Presentation is loading. Please wait.

Presentation is loading. Please wait.

R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS.

Similar presentations


Presentation on theme: "R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS."— Presentation transcript:

1 r Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS

2 r Slide # 2 GOAL Roche seeks approval recommendation: Valganciclovir (Val-GCV) is indicated for the treatment of CMV retinitis in patients with AIDS

3 r Slide # 3 AGENDA AND PRESENTERS DEVELOPMENT PROGRAM & STUDY RESULTS - Mary Jean Stempien, MD, MS INTRODUCTION - Mary Jean Stempien, MD, MS Director, Medical Research, Roche CLINICAL BACKGROUND - Daniel F. Martin, MD Associate Professor of Ophthalmology Emory University School of Medicine

4 r Slide # 4 EXPERTS Gary Koch, Ph.D. Professor of Biostatistics University of North Carolina, Chapel Hill Nancy C. Sambol, Pharm.D. Associate Clinical Professor Department of Biopharmaceutical Sciences University of California, San Francisco

5 r Slide # 5 CLINICAL BACKGROUND

6 r Slide # 6 CLINICAL BACKGROUND Daniel F. Martin, M.D. Associate Professor of Ophthalmology Emory University School of Medicine u Clinical Features of CMV Retinitis u Impact of HAART u Treatment Options

7 r Slide # 7

8 r Slide # 8

9 r Slide # 9

10 r Slide # 10


Download ppt "R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS."

Similar presentations


Ads by Google